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Abstract 
Background: Esophageal-cancer is the seventh most common-cause of cancer-related-
deaths in men. Cytochrome-P450-family-1-subfamily-B-polypeptide-1 (CYP1B1) plays a role 
in the metabolism of xenobiotics, and is associated with several cancers. Here we 
investigated the association between a genetic-variant, CYP1B1-rs1056836, with the clinical-
characteristics of patients with esophagus-squamous-cell-carcinoma (ESCC). 
Method: 117-patients with ESCC and 208 healthy-subjects were recruited. DNA was extracted 
and genotyped. Kaplan-Meier curves were utilized to assess overall and progression-free 
survival. The relationship between clinicopathological-data, disease-prognosis, and survival, 
were evaluated with the genotypes.  
Results: the genotypic frequency for GG, GC, and CC were 58.6%, 29.8%, 11.5% respectively 
in the healthy subjects and 51.8%, 36.14% and 12% in the ESCC group. An association 
between the GG genotype and stage of ESCC was found.  
Conclusion: Our findings suggest a relationship between the CYP1B1-rs1056836 genetic 
polymorphism and clinical features of ESCC, supporting further studies in larger-populations 
in different-ethnic groups, taking into account potentially important environmental-factors.  
 
Keywords: cytochrome p450, esophagus squamous cell carcinoma  
  
Introduction 
More than 450000 people worldwide are affected by esophageal carcinoma, and there has 
been a rapidly rising incidence. Esophageal cancer has been reported to be  the eighth most 
common cancer globally (1) and the seventh most common cause of cancer-related death in 
men (2). A large sex difference has been reported in esophageal carcinoma and morbidity 
and mortality rates are more than 4 times higher in men in comparison to women(2). 
Despite recent advances in diagnosis and treatment, the five-year survival rate for 
esophageal cancer patients ranges from 15-25%; this may be related to the late diagnosis of 
the disease; its aggressiveness, or the lack of efficient treatment strategies (3). Further 
studies are required to understand the underlying disease mechanisms for earlier diagnosis 
and predicting prognosis. Several polymorphisms in a number of genes have reported to 
have an association with the development of esophageal carcer (4).  There are also several 
genetic predisposing factors that contribute to ESCC such as genes involved in the cell cycle 
or differentiation (5), genes involved in folate metabolism (6) Epidermal Growth Factor 
Receptor Signaling Pathway, Epigenetic Factors, Somatic Mutational Signature and 
polymorphisms(7)  (e.g., cytochrome P450).  
Recent studies have revealed that the cytochrome P450, family 1, subfamily B, polypeptide 
1 is associated with several cancer types. Cytochrome P450 family 1, a member of 
cytochrome P superfamily, includes three members: CYP1A1, CYP1A2, and  CYP1B1 (8,9). 
The CYP1B1 gene is a 12 kilobase sequence located on 2p22-21 with 3 exons and 2 introns 
and gives rise to a 5.2-kb mRNA. CYP1B1 has a high expression rate in some tissues such as 
uterus, breast, and prostate but barely detectable in the liver(10). Several studies have 
shown that CYP1B1 metabolizes various potential human carcinogens such as polycyclic 
aromatic hydrocarbons and heterocyclic amines and also overexpression has been reported 
in different tumor tissues (11). CYP1B1 accelerates estrogen hydroxylation reactions such as 
4-hydroxylation of 17β estradiol (E2), resulting in the production of 4-hydroxyestradiol 
which has a reduced activity. This conversion can result in tumor initiation (12). Hence, it 
appears that CYP1B1 may play an important role in the development and progression of 
tumors and has the potential to be a tumor biomarker and a target for anticancer drugs 
(13). More than 50 genetic variations have been identified affecting the CYP1B1 protein. The 
Rs1056836 polymorphism, also known as 4326C/G, is one of these variations. It is located in 
the third exon of CYP1B1 and it can result in a change in amino acid from Leu to Val.  This 
polymorphism is associated with estrogen and progesterone receptor activity in breast 
cancer (14). It also increases the Km of the 4-hydroxylation of estradiol by 4 fold which 
would change the estradiol binding status of CYP1B1 (15). This polymorphism is associated 
with a higher risk of cancers of the prostate (16), lung (17,18), larynx (19 )and endometrium 
(20) but not with breast ( 21) or colorectal cancer (22).Despite the lack of expression in 
hepatic tissue CYP1B1- rs1056836 has been found to be associated with elevated risk of 
hepatocellular carcinoma among HBsAg-positive individuals, in whom the risk increases by 
13.9 fold among smokers and also induces a high risk of cirrhosis in patients with 
hepatocellular carcinoma (23). The variation is also associated with concentrations of T4, 
FT3, and FT4 in the serum of polycystic ovary syndrome patients. Another study has 
reported a strong association between CYP1B1 – rs9341266 and ESCC risk (24). With regards 
to these findings, we designed this study to determine whether there is an association 
between the CYP1B1-rs1056836 polymorphism with clinical outcomes and features of 
esophagus squamous cell carcinoma patients. 
Materials and methods 
Ethics statement 
This study is approved by Mashhad University of Medical science. (MUMS, Mashhad, 
I.R.Iran) 
Patients and controls 
One hundred and seventeen patients who had been diagnosed with esophageal squamous 
cell carcinoma in Omid Hospital of Mashhad Medical University from May 2006 to August 
2014 were selected, for the case group in the study. The inclusion criteria were: locally 
advanced or metastatic ESCC. The 224 subjects in the control group were healthy people 
who had took part in the Mashhad Stroke and Heart Atherosclerotic Disorders (MASHAD) 
cohort study as previously described (25). The inclusion criteria for the control group 
included a lack of history in diseases such as myocardial infarction, cancer, infectious 
disease, or family backgrounds for similar conditions such as stroke and type II diabetes. 
Samples were got collected from paraffin embedded blocks fixed in formalin, and Nine-mm 
slices were processed serially. 
Genotyping 
QIAamp® DNA Mini-Kit (Qiagen, San Diego, CA) has been used for genomic DNA extraction 
from peripheral blood, according to manufacturer's approved protocol.  NanoDrop®-1000-
Detector (NanoDrop-Technologies, Wilmington, USA) was used to determine the DNA's 
concentration and purity. In order to analyze CYP1B1- rs1056836 genotype polymorphism, 
we used Taqman®-probes-based assay. Polymerase chain reaction amplification was 
performed in a 12.5 µl final reaction volume containing 10-20 ng/µl of DNA, and TaqMan® 
Universal Master Mix with speciﬁc primers and probes (C_3099976_30; Applied Biosystems 
Foster City, CA). To assess samples allelic content, ABIPRISM-instrument and SDS version-2.0 
software were applied (26, 27). More than 10% of the samples were randomly selected for 
the double check and the results were concordant. 
Statistical analysis 
All the analyses were accomplished two-sided with statistical significance set to 0.05 
(P<0.05). Data analysis conducted using SPSS-20 software (SPSS Inc., IL, USA).To report ESCC  
patients Descriptive statistics, mean and standard deviations(SD) were assessed in terms of 
the continuous variables and for categorical variables, frequencies and percentages were 
used. We used Pearson χ distribution In order to evaluate Hardy–Weinberg equilibrium 
(HWE) aberrations, and the assessed genotype and allele frequencies of CYP1B1 – 
rs1056836 polymorphism. Logistic regression (adjusted for age, sex and BMI) was used to 
evaluate whether there's an association between risk of ESCC for CC and CG genotype 
relative to GG genotype under recessive genetic model. For ESCC risk assessment, odd ratio 
(OR) and its corresponding 95 % confidence interval (CI) has been applied. To assess the 
relationship between CYP1B1- rs1056836 and clinicopathological characteristics Pearson’s 
chi-square χ2 test were applied for categorical variables while Student’s t tests utilized for 
continuous variables. Calculation of overall survival was performed using the  Kaplan-Meier 
method and subjects were observed from the day of treatment until the end point (which 
has been defined as death or censoring) and the data has been compared by Wilcoxon tests 
and log-rank. In Cox’s proportional hazard model univariate analysis of significant prognostic 
variables was included. In order to evaluate the orientation and significance of the effect, 
the Hazard ratio was utilized. 
Results 
clinicopathological characteristics of population 
The clinicopathological characteristics of patients are summarized in table 1. The median 
age of the participants was 58±11 and BMI was 19.9±5.2.  45.3% of patients were female 
and 54.7% were male. In 1.9% of patients, cancer cells spread into the lining of the esophagus 
(T1 status), in 5.6% of cases, invaded cells spread into although not through the muscle wall of the 
esophagus while in about 21.5% of them, cancer cells spread through the muscle wall of the 
esophagus into surrounding tissues. Finally, 71% of participants were in T4 status, where cancer cells 
penetrate into surrounding tissues. In 63% of cases, tumor cells were absent from regional 
lymph nodes and nodal status determined as N0 while in 27% of the cases lymph node 
metastasis was present, defined as N1 to N3. In 15.4% distant metastasis was observed. To 
assess the influence of patients features on clinical outcome, the progression-free survival 
(PFS) and overall survival (OS) were analyzed and we found an association between this 
polymorphism and stage of the disease  
Genetic variant association with ESCC 
We conducted DNA extraction from peripheral blood and ESCC tissue samples and 
genotyped all the samples with minimum errors. The duplicate check was performed on 
randomly selected samples and no deviations were found. Overall 291 age and sex matched 
subjects (208 healthy controls and 83 ESCC) were included in our study (table 2). The 
distribution of CYP1B1-rs1056836 in the studied population was in agreement with Hardy-
Weinberg equilibrium (HWE) (P>0.05) which is shown in table 2 in addition to genotype 
frequencies. The frequency of the minor allele (C) was 0.3. the genotypic frequency for GG, 
GC, and CC are respectively 58.6% , 29.8%, 11.5% in the control group and 51.8%, 36.14% 
and 12% in the case group. In table 3 genotype frequencies were evaluated with respect to 
clinicopathological characteristics of ESCC patients under the recessive genetic model. 84% 
of women had a GG genotype. With respect to the recessive genetic inheritance model, we 
found an association between the GG genotype and stage of ESCC. Statistically significant 
results were not found for this variation and risk of ESCC. According to Kaplan-Mayer curves, 
patients with GC/CC genotype had a significantly shorter overall survival with mean range of 
51.6±7.5 months in comparison with GG patients with mean range of 68±8.89 months 
(figure1- a). Furthermore, the PFS of cases with GC/CC genotype was 34.9±5.9 vs GG 
genotypes with PFS of 46.3 ± 8.9 months. (figure 1-b). 
Discussion  
To the best of our knowledge this is the first study demonstrates that CYP1B1 – rs1056836 
was associated with ESCC patients. Devlin et.al in a study on CYP1B1 protein expression in 
the rat model of esophageal tumorigenesis showed that CYP1B1 protein has an extremely 
low expression levels in esophageal tissues of the normal rat while expressed in high levels 
in esophageal hyperplasia and squamous cell carcinoma. This study claimed that expression 
of CYP1B1 might be an early event in rat tumor formation and together with its regulatory 
mechanisms of expression, might play a role in the development of high-grade dysplasia to 
carcinoma (28), which is in agreement with our findings. 
Similar to these findings another study reported elevated levels of CYP1B1 in the tongue, 
esophagus, lung and colon of the mice with short-term exposure to tobacco smoke. They 
investigated the impact of tobacco smoke condensate and benzo[a]pyrene on the 
expression of CYP1B1 in vitro and in vivo. The in vitro phase conducted on H2122, SCC450 
and MSKLeuk1 cell lines, derived from human non-small cell lung adenocarcinoma, 
esophageal squamous cell carcinoma and dysplastic oral leukoplakia lesion respectively. The 
results showed that both tobacco smoke condensate and benzo[a]pyrene result in elevated 
levels of CYP1B1 protein and mRNA in cell lines. Also, treatment with tobacco smoke-
induced AhR signaling leads to CYP1B1 induction (29). We did not find any statistically 
significant association between risk of ESCC and rs1056836 which is in agreement with 
previously published studies. An etiological case-control study on ESCC found no significant 
difference between allelic frequencies of CYP1A1 3'-UTR, CYP1B1, CYP2E1, CYP1A1 exon7, 
and, CYP2A6 (del) in case and control groups (30). Also in another case-control study 
conducted in Kashmir India on the association of Leu432Val Polymorphism of CYP1B1 on 
ESCC, the frequency of both Val432Val and Leu432Val genotypes reported equal in both 
case and control group (31). The association of CYP1B1 – rs1056836 with different cancers 
have been studied intensively.  Li et.al in a study of over 724 SCCHN (Squamous Cell 
Carcinoma of the Head and Neck) cases and 1226 cancer-free controls, found no significant 
effect of CYP1B1-rs1056836 in SCCHN (32). Similar to these findings, Yon Ko et.al did not 
find any important impact for CYP1B1 – rs1056836 in SCCHN but reported it as a  
susceptibility factor in smokers (33 ). CYP1B1–rs1056836 polymorphism has been shown to 
be associated with progression-free survival and response rate of non‑small cell lung cancer 
(NSCLC) patients treated with docetaxel, and the GG genotype has been reported to result 
in shorter progression-free survival in comparison to other genotypes (17). Also in a meta-
analysis on 6501 subjects with lung cancer CYP1B1-rs1056836 were found to be associated 
with the risk of lung cancer and Val allele of CYP1B1 codon 432 is reported as a low 
penetrance risk factor in this cancer which is more common in lung adenocarcinoma, 
Caucasians or in smokers (18). Peng-Ju Yu et.al in a case-control study in 2015 on 600 
subjects including healthy and laryngeal cancer patients, reported a significant difference in 
frequencies of rs1056827 and rs1056836 genotypes between case and control group and 
the G allele carriers of rs106836 had a lower risk of laryngeal cancer development in 
comparison to C allele carriers (19). In approval of these findings Diljit Kaur-Knudsen et.al 
reported decreasing risk of tobacco-related cancer with CG and GG genotypes of CYP1B1- 
rs1056836 versus CC genotype but they did not found any association between CYP1B1-
rs1056836 and ischemic heart disease (IHD), chronic obstructive pulmonary disease (COPD), 
ischemic cerebrovascular disease (ICVD),  cancer overall and female cancers (34). A meta-
analysis on Estrogen-Related Pathway Genes polymorphisms has reported associations 
between CYP1B1 and CYP1A1 genotypes and risk of prostate cancer (16) which is supported 
by several other studies (16,35-38). 
A strength of the current study is that it was performed in a well-characterized cohort of 
individuals, with or without ESCC in a cohort of 10 years cases with clinical outcome (OS and 
PFS). The main limitations were the cross-sectional design and modest sample size. 
Additionally, it is possible that other lifestyle characteristics such as diet have an influence 
on the outcome.  
This study indicates that CYP1B1-rs1056836 can be as a potential stage biomarker for ESCC 
patients, but further studies with larger samples sizes in different ethnic groups are required 
to approve our findings in other populations. 
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Figure 1. Kaplan–Meier survival curves. (a) Overall survival (OS) and (b) Disease-free survival 
(DFS) based on different genotypes of CYP1B1 rs1056836 polymorphism. P-values were 
calculated with the log-rank test. 
